AstraZeneca attractive in near term but patent cliffs loom, says brokerProactive Investors • 12/14/22
AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy ZoneInvestors Business Daily • 12/13/22
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early TrialsBusiness Wire • 12/09/22
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast CancerBusiness Wire • 12/08/22
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03Business Wire • 12/07/22
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022Business Wire • 11/30/22
Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca's Manufacturing Site in West Chester, OhioBusiness Wire • 11/29/22
AstraZeneca adds focus on personalised cancer cell therapy with US$320mln acquisitionProactive Investors • 11/29/22
AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell TherapyBusiness Wire • 11/29/22
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programmeGlobeNewsWire • 11/28/22
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022Business Wire • 11/22/22
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsBusiness Wire • 11/16/22
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesPRNewsWire • 11/14/22
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric CancerBusiness Wire • 11/14/22